Azetidines as MEK inhibitors for the treatment of proliferative diseases
US7803839B2 · kind B2 · utility
28Cited by
5References
68Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 5, 2006 |
| Grant date | Sep 28, 2010 |
| Priority date | — |
| Expiry date | Feb 1, 2027 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D471/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.